Skip Navigation


Carcinogenesis Advance Access originally published online on October 10, 2006
Carcinogenesis 2007 28(3):572-583; doi:10.1093/carcin/bgl193
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
28/3/572    most recent
bgl193v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Google Scholar
Right arrow Articles by Li, B.
Right arrow Articles by Spencer, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, B.
Right arrow Articles by Spencer, D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 The Author
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Conditional Akt activation promotes androgen-independent progression of prostate cancer

Benyi Li1,2,3,*, Aijing Sun1, Hyewon Youn1, Yan Hong1, Paul F. Terranova2,3, J.Brantley Thrasher1,3, Pingyi Xu1,4,* and David Spencer5

1 Department of Urology, The University of Kansas Medical Center Kansas City, KA 66160, USA
2 Department of Molecular and Integrated Physiology, The University of Kansas Medical Center Kansas City, KA 66160, USA
3 Kansas Masonic Cancer Research Institute, The University of Kansas Medical Center Kansas City, KA 66160, USA
4 Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University Guangzhou 510080, China
5 Baylor College of Medicine, Department of Immunology Houston, TX, 77030.

*To whom correspondence should be addressed at: KUMC Urology, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. Tel: +1 913 588 4773; Fax: +1 913 588 7625; Email: bli{at}kumc.edu

*Correspondence may also be addressed to: Pingyi Xu, Department of Neurology, Sun Yat-sen University, Guangzhou 510080, China. Tel: 130 02087616; Email: pxu{at}kumc.edu

Aggressive androgen-independent (also termed as hormone-refractory) prostate cancer is a major clinical obstacle because there is no means to cure. Previous studies have shown that Akt activation is associated with prostate cancer progression from androgen-dependent to androgen-independent stage. However, its causative role in this process has not been established. One of the major limitations is the lack of a well-controlled inducible system to study Akt involvement. Recently, we developed a novel inducible Akt (iAKT) system based on a chemically induced dimerization (CID) approach. This system allows for conditional activation of Akt in a physiological setting. Utilizing this iAKT system, we found that Akt activation prevented cell death after serum withdrawal and promoted cell proliferation in the absence of androgen in vitro in human prostate cancer LNCaP cells, which should stop growing after androgen withdrawal or even die after serum starvation. The iAKT-induced death protection and growth promotion were further demonstrated in vivo using a transgenic mouse model that expresses the iAKT system conditionally in the prostate epithelium. Most importantly, in a mouse xenograft model derived from LNCaP cells, iAKT activation promoted tumor growth in castrated animals by enhancing cell proliferation and inhibiting apoptosis. Taken together, our data suggest that Akt activation is playing a causative role in androgen-independent progression of prostate cancer. This study provides a significant relevance of Akt-targeted therapy for hormone-refractory prostate cancers.

Abbreviations: AR, androgen receptor; BrdU, 5-bromo-2-deoxyuridine; CDK, cyclin-dependent kinase; cFBS, charcoal-stripped FBS; CID, chemically induced dimerization; IACUC, institutional Animal Care and Use Committee; iAKT, inducible Akt; IGF, insulin-like growth factor; PDK1, phosphatidylinositol-dependent kinase 1; PI3K, phosphatidylinositol 3-kinase; PH, pleckstrin-homology domain; PIN, prostatic intraepithlial neoplasia; PSA, prostate-specific antigen; PTEN, phosphatase and tensin homolog; RIPA, radio-immunoprecipitation assay

Received July 26, 2006; revised September 25, 2006; accepted October 2, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
R. L. Vinall, K. Hwa, P. Ghosh, C.-X. Pan, P. N. Lara Jr., and R. W. de Vere White
Combination Treatment of Prostate Cancer Cell Lines with Bioactive Soy Isoflavones and Perifosine Causes Increased Growth Arrest and/or Apoptosis
Clin. Cancer Res., October 15, 2007; 13(20): 6204 - 6216.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C. Blanco-Aparicio, O. Renner, J. F.M. Leal, and A. Carnero
PTEN, more than the AKT pathway
Carcinogenesis, July 1, 2007; 28(7): 1379 - 1386.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
C. F. MacManus, J. Pettigrew, A. Seaton, C. Wilson, P. J. Maxwell, S. Berlingeri, C. Purcell, M. McGurk, P. G. Johnston, and D. J.J. Waugh
Interleukin-8 Signaling Promotes Translational Regulation of Cyclin D in Androgen-Independent Prostate Cancer Cells
Mol. Cancer Res., July 1, 2007; 5(7): 737 - 748.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.